{
    "clinical_study": {
        "@rank": "47072", 
        "brief_summary": {
            "textblock": "This treatment protocol will serve as a mechanism to continue to provide ficlatuzumab to\n      patient 0001-000412, who was previously enrolled under protocol P05538 and whom the\n      investigator believes is deriving clinical benefit from ficlatuzumab treatment."
        }, 
        "brief_title": "Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient", 
        "condition": "Patient 0001-000412 Under Study P05538", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Per original P05538 protocol\n\n        Exclusion Criteria:\n\n          -  Per original P05538 protocol"
            }, 
            "gender": "Female", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "March 14, 2014", 
        "id_info": {
            "nct_id": "NCT02090127", 
            "org_study_id": "AV-299-13-103S"
        }, 
        "intervention": {
            "description": "humanized anti-hepatocyte growth factor (HGF) monoclonal antibody IV administration at 16.5mg/kg every 2 weeks with a \u00b12 day window around dosing dates, as long as subject is deriving clinical benefit as determined by the Investigator", 
            "intervention_name": "ficlatuzumab", 
            "intervention_type": "Drug", 
            "other_name": [
                "AV-299", 
                "SCH 900105"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 14, 2014", 
        "link": {
            "url": "http://clinicaltrials.gov/show/NCT00725634"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas"
                }, 
                "name": "START"
            }, 
            "investigator": {
                "last_name": "Amita Patnaik, MD", 
                "role": "Principal Investigator"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Expanded Access Protocol to Provide Ficlatuzumab to P05538 Patient 0001-000412", 
        "overall_contact": {
            "email": "fpayumo@aveooncology.com", 
            "last_name": "Francis Payumo", 
            "phone": "617-299-5867"
        }, 
        "overall_status": "Available", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02090127"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "AVEO Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AVEO Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Expanded Access", 
        "verification_date": "March 2014"
    }
}